

THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT. THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.



An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients with Dementia



WP3: Foundations of the Clinical Decision Support Services for the management of multimorbid elderly patients with dementia

D3.5: Safety Assessment of the CDSM Suite

Contractual Date of Delivery to the EC: M18 (31 Dec 2022)

Actual Date of Delivery to the EC: 31 March 2023 as extended due date with the European Commission (EC) Project Officer (PA) agreement

Participant(s): ⁴UOB, ¹EXYS, ²Fraunhofer, ⁹SRDC, ¹⁰OCT

Author(s): ⁴Bilal Ahmad, ⁴Omid Pournik, ⁴Sarah N. Lim Choi Keung, ⁴Theodoros N. Arvanitis, ²Yehya Mohamad, ²Carlos A. Velasco, ²Henrike Gappa, ⁹Mert Gencturk, ¹⁰Seif Ben Badder, ¹⁰Lionello Ferrazzini, ⁹Gokce Banu Laleci Erturkmen, ¹Angelo Consoli

Type (P-prototype, R-report, O-other, ORDP-Open Research Data Pilot, DEM-Demonstrator, ET-Ethics): R-report

Dissemination level (PU-Public, CO-Confidential): PU

Version: 1v3

Total number of pages: 46



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945169.

THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT. THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.

Executive Summary

The task will provide the necessary confidence for CAREPATH Clinical Decision Support Modules (CDSM) to be used in integrated care and healthcare services. This aims to perform a safety assessment of CDSM with a particular focus on the Medical Devices Regulation (MDR). It will support compliance activities, by establishing a classification for CDSM, and in collaboration with the other Work Packages and create a technical report that can be used for certification. It also specifies a roadmap for certification, which might enhance future exploitation of CAREPATH to a fully-fledged service. University of Birmingham (UOB) has led the task, performed the safety assessment, and wrote the assessment document. UOB, SRDC, Fraunhofer and EXYS have worked collaboratively in populating the assessment document with the relevant information. In this document, the result of these activities is reported as an output of Task 3.5.

THIS DOCUMENT IS EXTRACTED FROM THE FULL DELIVERABLE, AS THE ORIGINAL DELIVERABLE CONTAINS CONFIDENTIAL INFORMATION FOR THE COURSE OF THE PROJECT. THE FULL DELIVERABLE CONTENT WILL BE PUBLISHED AFTER THE END OF THE PROJECT.

Table of Contents

1	INTRODUCTION	6
1.1	PROJECT INFORMATION	6
1.2	DOCUMENT SCOPE	6
1.3	DOCUMENT STRUCTURE	6
2	MDR DEVICE AND IN-VITRO DIAGNOSTIC MEDICAL DEVICE	7
2.1	BACKGROUND	7
2.1.1	<i>MDR Classification</i>	8
2.1.2	<i>Medical Device Classification Purpose</i>	8
2.1.3	<i>Elements of MDR</i>	8
2.1.4	<i>Practical Relevance of Classification</i>	9
2.1.5	<i>Key Characteristics for Qualification as a Medical Device</i>	10
2.1.6	<i>Rule 11, Annex VIII MDR</i>	10
2.1.7	<i>Conformity Assessment</i>	11
2.1.8	<i>Clinical Evaluation and Investigation</i>	12
2.1.9	<i>Need for Clinical Evaluation and Investigation</i>	12
2.1.10	<i>Post Market Surveillance and Traceability</i>	13
2.2	RISK METRIC IN RELATION TO MDR	13
2.2.1	<i>Risk Dimension</i>	13
2.2.2	<i>Risk Acceptability</i>	14
2.3	STEPS TO MDR	14
2.3.1	<i>Common Specifications</i>	15
2.3.2	<i>Software Lifecycle</i>	15
2.3.3	<i>Unique Identifier for a Device</i>	15
3	MDR CLASSIFICATION FOR CAREPATH	16
3.1	METHODOLOGY	16
3.2	DEVELOPMENT AND RESULTS	16
3.3	INSTRUCTIONS FOR USE	17
3.4	CLASSIFICATION PRINCIPLES AND RULES	17
4	MDR AND CE MARK MODELLING FOR CAREPATH CDSM	17
4.1	DEFINITION OF INTENDED USE	18
4.1.1	<i>Clinical Guidelines</i>	19
4.1.2	<i>Advanced Early Warning Clinical Decision Support System</i>	19
4.1.2.1	Input to Advanced Early Warning and Monitoring Tools	20
4.1.2.2	The CDSS Drug-Drug Interaction Service (DIAS)	21
4.1.2.3	Drug Interactions Advisory Service Ontology	21
4.1.3	<i>Polypharmacy</i>	21
4.1.4	<i>Rule Engine</i>	22
4.2	DEVICE CLASSIFICATION ASSESSMENT INTO MDR	24
4.3	DEVICE CLASSIFICATION CATEGORIES (I,IIA,LLB,III)	24
4.4	HAZARD ASSESSMENT FOR DEVICE	25
4.4.1	<i>Hazard Control Measures</i>	25
4.4.2	<i>Hazard vs Benefits in a Device</i>	26
4.5	GENERAL SAFETY AND PERFORMANCE REQUIREMENTS	27
5	FUTURE ROAD MAP	28
6	CONCLUSIONS	30
7	REFERENCES	31
8	APPENDIX	32
9	DOCUMENT HISTORY	46